TRDA (Entrada Therapeutics) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


TRDA Entrada Therapeutics Inc TRDA
23 GF Score
Price $7.26
GF Value $0.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entrada Therapeutics Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Entrada Therapeutics's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

TRDA vs SABS, ACIU, AVXL: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Entrada Therapeutics's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entrada Therapeutics Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entrada Therapeutics's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Entrada Therapeutics's Margin of Safety % (DCF Earnings Based) falls into.


TRDA
23GF Score
Entrada Therapeutics Inc TRDA
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.26 is trading 689.1% above its estimated GF Value™ of $0.92. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $0.92 vs. price of $7.26 (689.1% above fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score

Get the complete analysis for TRDA

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.26
Price
$0.92
GF Value